Reduction of Experimental Cerebral Malaria and Its Related Proinflammatory Responses by the Novel Liposome-Based beta-Methasone Nanodrug
Jintao Guo, Judith H Waknine-Grinberg, Andrew J Mitchell, Yechezkel Barenholz, Jacob Golenser
BioMed Research International | HINDAWI LTD | Published : 2014
Cerebral malaria (CM) is a severe complication of and a leading cause of death due to Plasmodium falciparum infection. CM is likely the result of interrelated events, including mechanical obstruction due to parasite sequestration in the microvasculature, and upregulation of Th1 immune responses. In parallel, blood-brain-barrier (BBB) breakdown and damage or death of microglia, astrocytes, and neurons occurs. We found that a novel formulation of a liposome-encapsulated glucocorticosteroid, β-methasone hemisuccinate (nSSL-BMS), prevents experimental cerebral malaria (ECM) in a murine model and creates a survival time-window, enabling administration of an antiplasmodial drug before severe anemi..View full abstract
This work was supported by a grant from the Australian National Health and Medical Research Council, the Sir Zelman Cowen Universities Fund, and the Barenholz Fund.